Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 4, 2004, Pages 641-645

  Shoen, Carolyn M ^a   DeStefano, Michelle S ^b   Sklaney, Mary R ^a   Monica, Bobbi J ^a   Slee, Andrew M ^b   Cynamon, Michael H ^a,c  

^a Central New York Research Corporation   (United States)

^b DUPONT COMPANY   (United States)

^c SYRACUSE VA MEDICAL CENTER   (United States)

Author keywords

Animal models; Infectious diseases; Mycobacterium tuberculosis; Therapy

Indexed keywords

ANTIMYCOBACTERIAL AGENT; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; PNU 100480; RIFAMPICIN; SPARFLOXACIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIUM ISOLATE; CELL COUNT; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SHORT COURSE THERAPY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ACETAMIDES; ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; FEMALE; FLUOROQUINOLONES; ISONIAZID; MICE; MICE, INBRED C57BL; OXAZOLIDINONES; RIFAMPIN; TIME FACTORS; TUBERCULOSIS;

EID: 16544389763     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh124     Document Type: Article

References (21)

1. Bloom, B. R. & Murray, C. J. (1992). Tuberculosis: commentary on a reemergent killer. Science 257, 1055-64.
2. Iseman, M. D. (1993). Treatment of multidrug-resistant tuberculosis. New England Journal of Medicine 329, 784-91.
3. Cynamon, M. H., Klemens, S. P., Sharpe, C. A. et al. (1999). Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrobial Agents and Chemotherapy 43, 1189-91.
4. Ji, B., Lounis, N., Truffot-Pernot, C. et al. (1995). In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 39, 1341-4.
5. Klemens, S. P., Sharpe, C. A., Rogge, M. C. et al. (1994). Activity of levofloxacin in a murine model of tuberculosis. Antimicrobial Agents and Chemotherapy 38, 1476-9.
6. Sizemore, C. F., Quispe, J. D., Amsler, K. M. et al. (2002). Effects of metronidazole, tetracycline, and bismuth-metronidazole-tetracycline triple therapy in the Helicobacter pylon SS1 mouse model after 1 day of dosing: development of an H. pylori lead selection model. Antimicrobial Agents and Chemotherapy 46, 1435-40.
7. Alvirez-Freites, E. J., Carter, J. L. & Cynamon, M. H. (2002). In vitro and in vivo activities of gatifloxacin against Mycobacterium, tuberculosis. Antimicrobial Agents and Chemotherapy 46, 1022-5.
8. Barbachyn, M. R., Hutchinson, D. K., Brickner, S. J. et al. (1996). Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. Journal of Medicinal Chemistry 39, 680-5.
9. Reddy, M. V., Luna-Herrera, J., Daneluzzi, D. et al. (1996). Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice. Tubercle and Lung Disease 77, 154-9.
10. Klemens, S. P., Grossi, M. A. & Cynamon, M. H. (1994). Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrobial Agents and Chemotherapy 38, 2245-8.
11. Yoshimatsu, T., Nuermberger, E., Tyagi, S. et al. (2002). Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrobial Agents and Chemotherapy 46, 1875-9.
12. Ji, B., Lounis, N., Maslo, C. et al. (1998). In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 42, 2066-9.
13. Gray, D. F. & Mattinson, M. W. (1952). Detection of small numbers of tubercle bacilli from dispersed cultures, using mice, guinea pigs, and artificial media. American Review of Tuberculosis 65, 572-88.
14. Cynamon, M. H. & Sklaney, M. (2003). Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrobial Agents and Chemotherapy 47, 2442-4.
15. O'Brien, R. J. & Nunn, P. P. (2001). The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. American Journal of Respiratory and Critical Care Medicine 163, 1055-8.
16. O'Brien, R. J. & Vernon, A. A. (1998). New tuberculosis drug development. How can we do better? American Journal of Respiratory and Critical Care Medicine 157, 1705-7.
17. Lenaerts, A. J. M., Gruppo, V., Brooks, J. V. et al. (2003). Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrobial Agents and Chemotherapy 47, 783-5.
18. Sirgel, F. A., Donald, P. R., Odhiambo, J. et al. (2000). A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. Journal of Antimicrobial Chemotherapy 45, 859-70.
19. Jindani, A., Aber, V. R., Edwards, E. A. et al. (1980). The early bactericidal activity of drugs in patients with pulmonary tuberculosis. American Review of Respiratory Disease 121, 939-49.
20. Cooper, A. M., Callahan, J. E., Keen, M. et al. (1997). Expression of memory immunity in the lung following re-exposure to Mycobacterium tuberculosis. Tubercle and Lung Disease 78, 67-73.
21. Orme, I. M. (1987). The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. Journal of Immunology 138, 293-8.